Table 2.

Randomized trials comparing insulin detemir to NPH and glargine in basal-bolus regimen and as add-on to OADS

Study	Study duration (weeks)	Number of patients	Insulin therapy	Change in HbA1c (%)	Incidence (%) of hypoglycemia	Change in weight (kg)
						Majora	Nocturnal
Philis-Tsimikas et al38	20	165	detemird	−1.6	0	2.4	+1.2
		169	detemire	−1.5	1.2	4.7	+1.5
		164	NPH	−1.7	0	13.4	+1.6
Hermansen et al37	26	227	detemir + OADs	−1.8	NA	55% less	+1.2
		225	NPH + OADs	−1.9	NA	NA	+2.8
Rosenstock et al39	52	291	detemir + OAD	−1.4	0/pt-yr	1.3/pt-yr	+3.0
		291	Glargine	−1.5	NA	1.3/pt-yr	+3.9
Haak et al36	26	341	detemir + aspart	−0.2	<2	15.8	+1.0
		164	NPH + aspart	−0.4	<2	23.6	+1.8
Raslova et al35	22	195	detemir and aspart	−0.7	1.1	14.9	+0.51
		199	NPH and RHI	−0.6	0.5	17.5	+1.13
Rosenstock et al39	52	582	detemir and OAD	−1.4	no significant difference		+3.0
			glargine and OAD	−1.5			+3.9

^aMajor hypoglycemia is where patients are not able to treat themselves.

^dInsulin detemir administered in the morning.

^eInsulin detemir administered in the evening.